You searched for "funding"
Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow up
Chavanod (near Annecy), France, March 29, 2023 - Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, announced the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning Device.
The Sclera and Systemic Disorders (3rd Edition)
An interesting historical introduction captures the reader’s attention as the journey begins into exploring the peculiarities and pathologies of ‘dura tunica of Vesalius’, a term coined by anatomists of the middle ages. This refers to what we today identify as...Pathophysiology of diabetic macular oedema: why combination therapy may be better
The prevalence of diabetes has continued to increase over the years. It is currently estimated that there are 382 million with diabetes worldwide in 2013, and that this figure is expected to rise to 592 million by 2035 [1]. In...
Stromal cell alignment in damaged cornea
Stromal keratocytes are responsible for wound healing in the cornea following damage. Keratocytes at the site of injury become activated and differentiate to myofibroblasts which secrete extracellular matrix (ECM) to close the wound, a response mediated by transforming growth factor...
CD40L activation of human RPE cells
Age-related macular degeneration (AMD) is the leading cause of reduced visual acuity in the elderly worldwide. The risk factors involved in AMD include smoking and diet, while genetics have been shown to have a significant role. Recently a link between...
Features from screening programme referrals pre and post pandemic
In this study the authors conducted an analysis of demographics, referral rates and prevalence of various ophthalmic assessments among children referred to an ophthalmologist through the UCI eye mobile programme. They further evaluated the influence of socio-economic factors and the...
